GLP-1 Medications vs.
Qsymia: How the Options Compare

No reviewed randomized trial directly assigned adults to current Wegovy or Zepbound versus Qsymia. Separate trial results are context, not evidence that one medicine is superior for an individual. For other comparisons, see Luma Health’s guides to GLP-1 medicines versus bariatric surgery and GLP-1 medicines versus endoscopic sleeve gastroplasty.

How the medicines differ

Qsymia combines phentermine, a sympathomimetic amine, with topiramate in one daily extended-release capsule. Its label links phentermine’s effect to hypothalamic catecholamine release and reduced appetite; topiramate’s exact mechanism is unknown. Qsymia is not phentermine or topiramate alone, so combination evidence should not transfer to either separate medicine.^[1]

Wegovy and Zepbound work through incretin pathways. Wegovy is a GLP-1 receptor agonist, while Zepbound activates GIP and GLP-1 receptors. A statement about Wegovy does not automatically apply to Zepbound, another GLP-1 medicine, or a non-FDA-approved preparation. This comparison focuses on weekly Wegovy and Zepbound injections. Wegovy also has an oral formulation, which is not the STEP 1 regimen discussed below; Qsymia is a daily oral capsule.^{[2] [3]}

Selection starts with the label and the whole health picture

NIDDK’s common adult starting framework is body mass index (BMI) of at least 30, or at least 27 with a weight-related health problem. It does not guarantee suitability. NIDDK identifies likely benefit, side effects, health issues and other medicines, family history, and cost as factors for a clinician-led choice.^[4]

Qsymia is labeled for adults with obesity, or overweight plus at least one weight-related comorbid condition, as an adjunct to diet and activity. Its cardiovascular morbidity and mortality effect is not established, nor is safety and effectiveness with other weight-loss products. Wegovy and Zepbound also have product-specific labels. This comparison does not support starting a combination independently.^{[1] [2] [3]}

Qsymia is contraindicated in pregnancy, glaucoma, hyperthyroidism, monoamine oxidase inhibitor use or use within 14 days after stopping, and certain hypersensitivity situations. Wegovy and Zepbound are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), and relevant serious hypersensitivity. These are examples, not a complete screen.^{[1] [2] [3]}

What separate trials show—and what they cannot compare

In EQUIP, adults with BMI at least 35 received placebo or studied controlled-release phentermine/topiramate regimens with a reduced-energy diet. At 56 weeks, the primary analysis reported mean change of −10.9% with the 15/92 combination and −1.6% with placebo. CONQUER enrolled adults aged 18–70 with BMI 27–45 and at least two specified comorbidities. At 56 weeks, mean changes were −7.8% and −9.8% in its two studied combination groups, versus −1.2% with placebo.^{[5] [6]}

SEQUEL extended selected CONQUER participants for 52 more weeks, totaling 108 weeks with lifestyle modification. Mean changes were −9.3% and −10.5% in the studied combination groups, versus −1.8% with placebo. This is extension-population follow-up, not a result for every original participant or separate components.^[7]

STEP 1 enrolled 1,961 adults without diabetes, with BMI at least 30 or at least 27 plus a weight-related condition. At 68 weeks of semaglutide 2.4 mg or placebo plus lifestyle intervention, mean change was −14.9% versus −2.4%. SURMOUNT-1 enrolled 2,539 adults without diabetes for 72 weeks, including 20-week escalation. Mean changes ranged from −15.0% to −20.9% with studied tirzepatide regimens and were −3.1% with placebo.^{[8] [9]}

Pregnancy safeguards are meaningfully different

Pregnancy is a Qsymia contraindication. Its label says Qsymia can cause fetal harm and recommends a negative pregnancy test before treatment and monthly during treatment for patients who can become pregnant, with effective contraception. Qsymia is available through a Risk Evaluation and Mitigation Strategy (REMS). Its Medication Guide warns of birth defects including cleft lip and cleft palate with exposure during pregnancy.^[1]

For weight reduction, Wegovy and Zepbound direct discontinuation when pregnancy is recognized; weight loss offers no benefit during pregnancy and may cause fetal harm. Do not assume Qsymia’s monthly-testing and REMS process for incretin products, or minimize Qsymia’s specific embryo-fetal risk. Contact the prescribing team promptly about pregnancy plans or possible pregnancy rather than substituting treatment independently.^{[1] [2] [3]}

Monitoring and side-effect questions are not the same

Qsymia’s label calls for electrolytes, including bicarbonate, and creatinine before and during treatment. It warns about metabolic acidosis, decreased renal function, mood or sleep disorders, suicidal behavior or ideation, cognitive effects, and urgent eye symptoms related to acute myopia or secondary angle-closure glaucoma. Kidney stones, reduced sweating and overheating, and seizure risk with abrupt withdrawal are additional Qsymia concerns. These are not instructions for self-adjusting treatment.^[1]

Wegovy and Zepbound commonly have gastrointestinal adverse effects. Their labels also warn about severe gastrointestinal reactions, volume-depletion-related kidney injury, gallbladder disease, pancreatitis, and serious hypersensitivity. Both address hypoglycemia with insulin or an insulin secretagogue, retinopathy monitoring, and reported aspiration during anesthesia or deep sedation. Wegovy and Zepbound are not recommended in severe gastroparesis.^{[2] [3]}

Long-term care includes a continuation and stopping plan

NIDDK lists Qsymia, Wegovy, and Zepbound among FDA-approved medicines for long-term use. It notes that a clinician may advise ongoing treatment when a medicine helps and serious side effects are absent, while some weight regain is probable after stopping. Nutrition, activity, symptom reporting, medication review, access, and follow-up belong in the initial decision.^[4]

Branded Wegovy and Zepbound labels and trials concern those named FDA-approved finished drug products and their studied regimens. They do not establish the quality, bioequivalence, safety, or effectiveness of a compounded preparation. A compounded product must not be described as the same as an FDA-approved product or as having branded trial results.

1. Which exact FDA-labeled product is under consideration? Confirm the product, route, indication, and label.
2. Which risks change the choice? Review pregnancy plans, MTC/MEN 2 history, eye history, mood and cognition, gastrointestinal and kidney concerns, and every medicine or supplement.
3. What monitoring and urgent-symptom plan is needed? Ask what will be checked, which symptoms warrant prompt contact, and how procedures change the conversation.
4. What is the continuity plan? Discuss nutrition and activity support, follow-up, access, and clinician-guided changes if tolerability or coverage changes.

These questions support a shared decision, not a self-directed medication choice. Visit Luma Health’s treatment information page or read GLP-1 real-world effectiveness for related education.

Frequently asked questions